Head OfficeClinuvel Pharmaceuticals Limited, Tel: +61 3 9660 4900 |
Swiss OfficeNeuhofstrasse 3D Tel: +41 41 767 4545 |
US Office30 Broad Street Tel: +1 646 480 4810 |
Clinuvel receives a large number of inquiries every day. For a list of frequently asked questions, including information on projected release dates and trial participation please click here.
For more information on Clinuvel’s program for SCENESSE® in vitiligo, please go to http://www.clinuvel.com/vitiligo.
There are a number of misconceptions about the interaction between sunlight and skin. In this two part post... Read more...
It’s estimated that more than 9,000 Americans will die from melanoma this year and 76,000 new cases of the... Read more...
Young adults are the age group most likely to seek a tan, with research showing that people under the age of... Read more...
Part Four - The impact of Erythro...Mikey's quality of life, like all patients with Erythropoietic Protoporphyria (EPP), is severely affected. Severe pain f... Watch now |
Quick! I need Sunburn Relief! Rem...There are many remedies available to help provide relief from the symptoms of sunburn. Treatment of sunburn can include:... Watch now |
Understanding Vitiligo - Causes &...Vitiligo is a common pigmentary disorder in which the pigment producing cells of the skin (melanocytes) are absent or do... Watch now |
Company HistoryThe technology behind Clinuvel’s lead drug, SCENESSE® (afamelanotide), has been in research and development since the 1980s when a small team of scientists set out to investigate methods of preventing skin cancer in humans. Clinuvel licensed this technology an... Read more |
